IO Biotech (IOBT) furnishes Q3 2025 results press release (8-K)

IO Biotech, Inc. (IOBT) furnished an 8-K announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025 and an operations update.

Rhea-AI Filing Summary

IO Biotech, Inc. (IOBT) furnished an 8-K announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025 and an operations update. The press release is attached as Exhibit 99.1.

The company states the information under Item 2.02 is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically referenced.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IO Biotech (IOBT) announce in this 8-K?

IO Biotech furnished a press release with quarterly financial results and an operations update for the period ended September 30, 2025.

Which period does the IO Biotech (IOBT) update cover?

The update covers the fiscal quarter ended September 30, 2025.

Where can I find the full details of IO Biotech’s update?

The full press release is attached as Exhibit 99.1 to the 8-K.

Is the information in IO Biotech’s 8-K considered filed?

No. It is furnished, not filed, and is not subject to Section 18 liabilities or incorporation by reference unless expressly stated.

Does the 8-K include financial figures for IO Biotech (IOBT)?

Figures are contained in the press release (Exhibit 99.1); the 8-K itself announces and furnishes that release.

What exhibit numbers are included with IO Biotech’s 8-K?

The filing includes Exhibit 99.1 (press release) and Exhibit 104 (cover page Inline XBRL).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 08:10 AM EST Learn about SEC filing dates

false 0001865494 0001865494 2025-11-14 2025-11-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 14, 2025

IO BIOTECH, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware		001-41008		87-0909276
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Ole Maaløes Vej 3

DK-2200 Copenhagen N

Denmark

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: +45 7070 2980

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		IOBT		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On November 14, 2025, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of the Company dated November 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IO BIOTECH, INC.
Date: November 14, 2025				By:		/s/ Mai-Britt Zocca
				Name:		Mai-Britt Zocca, Ph.D.
				Title:		Chief Executive Officer